Adage Capital Partners’s Structure Therapeutics GPCR Stock Holding History

Adage Capital Partners’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-250,000	Closed	-$11M	–	909
2024 Q3	$11M	Sell	250,000 -963,099	-79%	-$37.2M	0.02%	590
2024 Q2	$47.6M	Buy	1,213,099 +402,497	+50%	+$16.5M	0.09%	226
2024 Q1	$34.7M	Sell	810,602 -946,316	-54%	-$39.9M	0.07%	315
2023 Q4	$71.6M	Sell	1,756,918 -43,005	-2%	-$2.46M	0.15%	150
2023 Q3	$90.8M	Buy	1,799,923 +1,607,525	+836%	+$51.8M	0.21%	117
2023 Q2	$8M	Sell	192,398 -100,000	-34%	-$2.8M	0.02%	605
2023 Q1	$6.96M	Buy	+292,398	New	+$6.87M	0.02%	672

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Adage Capital Partners's GPCR Position: Q4 2024 in Review

Adage Capital Partners sold out of Structure Therapeutics (GPCR) in Q4 2024, closing a stake of 250,000 shares — an estimated $11M sold.

Adage Capital Partners first reported a position in GPCR in Q1 2023 and held it in 7 quarters. The position peaked at $90.8M in Q3 2023. 164 funds tracked by Wall St. Rank hold GPCR as of Q4 2024.

Adage Capital Partners reported no remaining Structure Therapeutics position as of Q4 2024 after selling out during the quarter.
Adage Capital Partners sold 250,000 Structure Therapeutics shares in Q4 2024, an estimated $11M.
Adage Capital Partners first reported a position in Structure Therapeutics in Q1 2023 and held it in 7 quarters.
Adage Capital Partners's Structure Therapeutics position peaked at $90.8M in Q3 2023.
164 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.